Capital Group Investment Management PTE. LTD. Has $4.04 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital Group Investment Management PTE. LTD. trimmed its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,171 shares of the biopharmaceutical company's stock after selling 4,176 shares during the period. Capital Group Investment Management PTE. LTD.'s holdings in Alnylam Pharmaceuticals were worth $4,041,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ALNY. Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $35,000. Versant Capital Management Inc lifted its position in Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 83 shares during the period. Finally, IFP Advisors Inc grew its position in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 47 shares during the period. 92.97% of the stock is owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. This represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ALNY has been the subject of a number of analyst reports. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, March 21st. StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday. Morgan Stanley cut their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Finally, Royal Bank of Canada upped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $315.58.

Alnylam Pharmaceuticals Stock Up 1.9 %

Shares of Alnylam Pharmaceuticals stock traded up $4.44 during trading hours on Wednesday, reaching $241.19. 320,945 shares of the company's stock were exchanged, compared to its average volume of 872,182. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a 50 day moving average of $247.91 and a two-hundred day moving average of $256.50. The stock has a market cap of $31.38 billion, a P/E ratio of -111.15 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.